Recently, the Shanghai Clinical Testing Quality Control Center announced the results of the first external quality assessment (EQA) of 2025. The Septin9 gene methylation testing project submitted by Tianjin Baikang Hexin Medical Laboratory — ProteinT＇s independent clinical-trial window — was fully consistent with the expected standard and passed the assessment.In recent years, liquid-biopsy technology has been increasingly used in the early screening, efficacy monitoring and recurrence assessment of tumors. Septin9 gene methylation, as a specific molecular marker of early colorectal cancer, has become an important auxiliary diagnostic tool. Passing this EQA fully demonstrates ProteinT＇s comprehensive strength in testing technology and quality control. ProteinT will continue to pursue excellence and continuously improve its laboratory capabilities to provide higher-quality, more credible testing services to clinicians and patients.About Tianjin Baikang Hexin Medical Laboratory. It is ProteinT＇s independent clinical-trial window, a national high-tech enterprise and a for-profit medical institution approved by the Health Commission. It is equipped with an Illumina NextSeq 500 sequencing system, Thermo Fisher Q-Exactive+/HF and AB SCIEX 4500 mass spectrometry systems, and a Bruker Avance III IVDr NMR spectrometer, with a total value exceeding 90 million RMB. It has served more than 100 tertiary hospitals and research institutes, with over 100,000 samples accumulated.

On June 10, 2025, Professor Li Jie, Founder and CEO of ProteinT (Tianjin) Biotechnology Co., Ltd., and Lu Jianfei, head of NMR business, visited the Xi＇an Regional Medical Testing Center (＂Xi＇an Medical Testing＂). Dr. Yan Hua, Vice President of Xi＇an Medical Testing, introduced the operation of its intelligent clinical testing laboratory, which fully leverages ＂Internet+＂ technology to build an AI platform, realizing intelligent operation across the entire process from sample sorting, testing and review to storage and re-testing.The delegation also visited the NMR spectroscopy metabolomics analysis platform, clinical microbiology laboratory and clinical molecular laboratory, and highly affirmed Xi＇an Medical Testing＇s innovative exploration of precision diagnosis and disease management based on multi-omics technologies.During the discussion, Professor Hao Xiaoke, Chief Scientist of Xi＇an Medical Testing, and Director Li Li welcomed the delegation. The two sides discussed the strategic cooperation of a ＂Clinical Liquid NMR Innovation Alliance,＂ aiming to jointly promote the clinical application of NMR spectroscopy in chronic-disease screening, metabolomics, intelligent diagnosis and medical AI integration, and to build a ＂standard + sample + computing power＂ trinity of NMR clinical-application infrastructure and a multi-party NMR innovation ecosystem.

The second episode of the first season of the ＂ProteinT Cup＂ Health Science Popularization Talent Show will go live on May 27 at 4 PM. Five shortlisted science-popularization videos will compete for the monthly championship. Audiences can participate interactively through on-site voting, and the voting results will form part of the selection. Everyone is welcome to scan the QR code to watch.